The frequencies of NPM1 (15.4%) and FLT3-ITD mutations (14%) are lower in AML patients from China [7], whereas the frequency of CEBPA mutations is higher (17.1%) [4]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.